PMID- 33460667
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20221207
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 274
DP  - 2021 Jun 1
TI  - A comparative study of acarbose, vildagliptin and saxagliptin intended for better 
      efficacy and safety on type 2 diabetes mellitus treatment.
PG  - 119069
LID - S0024-3205(21)00054-0 [pii]
LID - 10.1016/j.lfs.2021.119069 [doi]
AB  - As a complicated metabolic disorder, type 2 diabetes mellitus (T2DM) is becoming 
      a major health concern worldwide. Drugs including acarbose, saxagliptin and 
      vildagliptin are applied, but their efficacy is still required to be compared. 
      Therefore, the study aimed to evaluate the efficacy and safety of acarbose, 
      saxagliptin and vildagliptin in the treatment of T2DM. Ninety patients diagnosed 
      with T2DM were treated with acarbose, saxagliptin and vildagliptin, respectively 
      (30 patients for each drug). All patients were examined at 0, 4 and 12 weeks 
      after treatment with vital signs recorded. Fasting blood glucose and blood 
      biochemical indices were analyzed. In addition, fecal samples were taken for 
      microbial macrogenome sequencing and safety evaluation within 12 weeks after 
      treatment. Blood glucose level decreased at 4 and 12 weeks after treatment, and 
      the total cholesterol (TC) and high-density lipoprotein (HDL) levels at 12 weeks 
      were different. Genus abundance of intestinal flora was altered at different time 
      points. Acarbose increased Butyricimonas level first and then decreased it during 
      drug treatment. Saxagliptin increased Megamonas and decreased Turicibacter genus 
      level gradually. Pseudomonas, Klebsiella, Blautia, Faecalibacterium and Roseburia 
      levels fluctuated after Vildagliptin treatment, which increased fasting C-peptide 
      level greater than the other two drugs. Saxagliptin showed higher adverse 
      reactions than acarbose and vildagliptin. Collectively, acarbose, vildagliptin, 
      and saxagliptin can effectively reduce the HbA1c level and affect the intestinal 
      flora distribution in T2DM patients, and the adverse reactions of acarbose and 
      vildagliptin are less than saxagliptin, providing alternative strategies for the 
      treatment of T2DM.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Wang, Zhongchao
AU  - Wang Z
AD  - Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao 
      University, Qingdao 266000, PR China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Cancer Radiotherapy, The Affiliated Hospital of Qingdao University, 
      Qingdao 266000, PR China.
FAU - Hu, Jianxia
AU  - Hu J
AD  - Lab of Thyroid Diseases, The Affiliated Hospital of Qingdao University, Qingdao 
      266000, PR China.
FAU - Chen, Ying
AU  - Chen Y
AD  - Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao 
      University, Qingdao 266000, PR China.
FAU - Dong, Bingzi
AU  - Dong B
AD  - Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao 
      University, Qingdao 266000, PR China.
FAU - Wang, Yangang
AU  - Wang Y
AD  - Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao 
      University, Qingdao 266000, PR China. Electronic address: wangyg1966@126.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20210115
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptides)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Glycoside Hydrolase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9GB927LAJW (saxagliptin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
RN  - T58MSI464G (Acarbose)
SB  - IM
MH  - Acarbose/*therapeutic use
MH  - Adamantane/*analogs & derivatives/therapeutic use
MH  - Biomarkers/*analysis
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptides/*therapeutic use
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/analysis
MH  - Glycoside Hydrolase Inhibitors/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Vildagliptin/*therapeutic use
OTO - NOTNLM
OT  - Acarbose
OT  - Efficacy
OT  - Intestinal flora
OT  - Saxagliptin
OT  - Type 2 diabetes mellitus
OT  - Vildagliptin
EDAT- 2021/01/19 06:00
MHDA- 2021/04/13 06:00
CRDT- 2021/01/18 20:10
PHST- 2020/04/01 00:00 [received]
PHST- 2021/01/11 00:00 [revised]
PHST- 2021/01/11 00:00 [accepted]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
PHST- 2021/01/18 20:10 [entrez]
AID - S0024-3205(21)00054-0 [pii]
AID - 10.1016/j.lfs.2021.119069 [doi]
PST - ppublish
SO  - Life Sci. 2021 Jun 1;274:119069. doi: 10.1016/j.lfs.2021.119069. Epub 2021 Jan 
      15.